Guardant Health GH 深 沪
已收盘 02-06 16:00:00 美东时间
101.85
+3.490
+3.55%
华盛通- 最 高102.70
- 今 开100.77
- 成交量 227.18万股
- 最 低 97.52
- 昨 收 98.36
- 总市值 131.77亿
- 52周最高 120.74
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 34.88
- 委 比 -27.14%
- 总股本 1.29亿
- 历史最高 181.07
- 量 比 0.78
- 振 幅 5.27%
- 历史最低 15.81
- 每 手 1
- 风险率 25.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Guardant Health Announces Publication Of Study To Date Evaluating Circulating Tumor DNA For MRD Detection In Patients With Resected Stage III Colon Cancer After Surgery And Before Adjuvant Chemotherapy
Data published in Journal of Clinical Oncology supports routine use of circulating tumor DNA (ctDNA) testing in management of stage III colon cancer patientsGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology
02-02 21:17
Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients
Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients Guardant Health Inc. has announced the publication of results from the largest study to date evaluating circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection in patients with resected
02-02 21:05
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
Guardant nabs approval for Guardant360 companion diagnostic for Braftovi
The US FDA approved Guardant Health's (GH) Guardant360 CDx companion diagnostic for use in determining which patients could benefit from Pfizer's (PFE) Braftovi (encorafenib) as a colorectal cancer tr...
01-22 22:19
美股盘后 | Venture Global涨7.18%，Karman Holdings Inc.涨6.55%
Venture Global涨7.18%；Karman Holdings Inc.涨6.55%；Moderna涨3.79%
01-22 07:11
Reported Monday, Guardant Health And Merck Enter Multi-Year Global Collaboration To Develop Companion Diagnostics And Commercialize Oncology Therapies
Multi-year global collaboration will utilize Guardant liquid biopsy portfolio for the development of companion diagnostics for drug approvals
01-20 16:03
Cathie Wood's weekly recap: tilts to advanced air mobility, sells Meta
Cathie Wood’s ARK Invest repositions toward long-term innovation themes like advanced air mobility, autonomous transport, and gene editing during the last week, while reducing exposure to more matur...
01-12 20:30
Guardant Health guides Q4 and FY25 revenue above consensus
Guardant Health (GH) reported preliminary Q4 revenue of $280M, up 39% year over year and modestly above the consensus estimate of $267.75M, driven by strong oncology and screening volumes. The company...
01-12 14:19
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
